Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 14

1260TiP - Enhancing lung nodule discrimination with a novel cfDNA test: The cancer signature ensemble (CSE) approach

Date

21 Oct 2023

Session

Poster session 14

Topics

Population Risk Factor;  Laboratory Diagnostics;  Clinical Research

Tumour Site

Thoracic Malignancies

Presenters

Young-Chul Kim

Citation

Annals of Oncology (2023) 34 (suppl_2): S711-S731. 10.1016/S0923-7534(23)01942-7

Authors

Y. Kim1, H. Oh1, J.Y. Park2, S.H. Jang2, J. Cho3, Y.S. Park4, Y.W. Kim5, S.Y. Lee6, J. Yoon7, H. Kim8, S.Y. Kim8, T. Kim9

Author affiliations

  • 1 Department Of Internal Medicine, Chonnam National University Medical School & Chonnam National University Hwasun Hospital, 58128 - Hwasun county/KR
  • 2 Department Of Internal Medicine, Hallym University Sacred Heart Hospital, 431-070 - Anyang/KR
  • 3 Department Of Internal Medicine, Seoul National University Hospital, 03080 - Seoul/KR
  • 4 Department Of Internal Medicine, Seoul National University Hospital, 110-744 - Seoul/KR
  • 5 Department Of Internal Medicine, Seoul National University Bundang Hospital, 463-707 - Seongnam/KR
  • 6 Department Of Internal Medicine, Kyungpook National University, 41944 - Daegu/KR
  • 7 Division Of Pulmonology, Allergy And Critical Care, Department Of Medicine, Stanford University School of Medicine, 94305 - Stanford/US
  • 8 Dept Of Research, IMBdx Inc, 08506 - Seoul/KR
  • 9 Department Of Internal Medicine, Seoul National University and IMBdx Inc, 03080 - Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1260TiP

Background

Lung cancer is the leading cause of cancer-related deaths worldwide, with over 40% of patients diagnosed at stage IV, mainly due to difficulties in early detection. Although low-dose CT (LDCT) screening assists in early diagnosis, its high false-positive rate demands more accurate and minimally invasive biomarkers. In LDCT screening, about 5% of cases exhibit lung nodules with a 5% or higher risk of malignancy (Lung-RADS category 4); however, most are benign, with actual lung cancers representing only 0.6% of the total screened population. A diagnostic test is essential to avoid unnecessary invasive examinations and identify individuals at higher lung cancer risk. Other liquid biopsy approaches using restricted range of biomarkers have diagnostic limitations for early-stage cancers.

Trial design

We are recruiting participants aged between 50 and 80 years old who have a smoking history of at least 20 pack-years and are either current smokers or former smokers who quit within the past 15 years. Eligible individuals must have lung nodules identified on chest CT scans as Lung-RADS category 4B or 4X and be scheduled for a pathological diagnosis for lung cancer with TNM stage IA. Five participating hospitals are collecting whole blood (15mL) samples and sending them to a central laboratory, IMBdx. IMBdx is extracting cfDNA, performing quality control (QC), and assessing [1] whole-genome methylation patterns, [2] fragmentomics, and [3] copy number variations. The results will be integrated into a machine learning-based algorithm to establish a cancer signature ensemble (CSE) index as a 5-tier categorical indicator for differentiating malignant and benign nodules. A training set of 150 cases will be used to develop the CSE index, and its diagnostic performance will be validated in a validation set of 150 cases. The CSE index for lung cancer discrimination is expected to exhibit a sensitivity and specificity of 75% and 95%, respectively. The study's outcomes aim to reduce unnecessary CT follow-ups or invasive tissue sampling/surgery. Future research will explore its applicability as a screening test for non-smokers or individuals at lower lung cancer risk.

Clinical trial identification

Clinical Research Information Service of Korea (CRiS), Registration ID: KCT0007484.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

National Cancer Center Korea (HA22C0140000022).

Disclosure

J. Yoon: Financial Interests, Personal, Advisory Board: IMBdx. H. Kim, S.Y. Kim: Financial Interests, Personal, Full or part-time Employment: IMBdx. T. Kim: Financial Interests, Personal, Ownership Interest: IMBdx. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.